DSIP stands for delta sleep-inducing peptide. The name sounds like a promise: a peptide that brings on deep sleep. Researchers chased that idea for decades. The results never lined up with the name, and today it remains unapproved with mixed evidence.
Key takeaways
- DSIP is a nine-amino-acid peptide first isolated in the 1970s from rabbits put into a sleep-like state.
- Early studies raised hopes, but human results for insomnia were mixed and often small.
- Researchers have never fully agreed on how DSIP works in the body.
- DSIP (emideltide) is not FDA-approved. In July 2026, an FDA advisory committee voted against recommending it for compounding.
- Proven tools for better sleep exist, starting with CBT for insomnia and a medical check for sleep disorders.
Where DSIP came from
In the 1970s, Swiss researchers stimulated a part of the brain in rabbits to induce sleep, collected blood, and found a factor that seemed to increase deep "delta" sleep in other rabbits. They isolated a nine-amino-acid peptide and named it delta sleep-inducing peptide.
The name stuck, even though later research found DSIP's effects on sleep were less consistent than first hoped. Researchers also found it seemed to touch many other systems, including stress hormones and body temperature. Our DSIP peptide page has a quick overview.
What human studies found
Several small human studies were done in the 1980s and early 1990s:
- Some reported improvements in sleep in people with disturbed sleep or insomnia.
- A double-blind study in people with chronic insomnia found little or no meaningful improvement over placebo.
- Other short-term studies in chronic insomniacs reported only modest or inconsistent effects.
- One study measured natural DSIP-like levels in blood and found they rose and fell over the day, with odd links to body temperature and sleep stages.
The pattern is a classic one. Small early studies looked hopeful, and better-controlled studies did not confirm strong benefits. Research interest faded, and no large modern trials followed.
Hype vs evidence
| Online claim | What research shows |
|---|---|
| "Induces deep sleep" | The name came from early rabbit research. Human results were inconsistent. |
| "Fixes insomnia" | Mixed human data; a double-blind study in chronic insomnia found little benefit. |
| "Lowers stress hormones" | Some early findings, not well confirmed. |
| "Safe because it is natural" | Lab-made DSIP is not the same as natural body signals, and long-term safety is unknown. |
Why the early results did not hold up
Sleep research is tricky. People often sleep a bit better on any new treatment, including a placebo, simply because they expect to. Sleep also varies a lot from night to night, so small studies can show changes that are really just chance.
DSIP had other problems too. It breaks down quickly in the blood, and researchers never found a clear receptor for it in the brain. Without a clear target, it was hard to design better studies or explain mixed results. These are common reasons promising early compounds fade away.
Regulatory status in 2026
DSIP's drug name is emideltide. In April 2026, FDA said it would remove emideltide from Category 2 of its interim compounding lists, the group that raises significant safety concerns. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 7-6, with one abstention, against recommending emideltide for the 503A bulks list. It was the only one of seven peptides reviewed that the committee did not back.
DSIP remains an unapproved drug in the US. Products sold online as "research use only" are not made for human use. For athletes, unapproved substances may fall under WADA's S0 category, so check with your anti-doping organization.
Why sleep problems deserve a real checkup
Poor sleep is common, and it often has a fixable cause. A clinician can look for:
- Sleep apnea, especially if you snore or wake up tired
- Restless legs syndrome
- Depression or anxiety
- Pain or other health problems
- Medicines, caffeine or alcohol that disturb sleep
Self-treating with an unapproved peptide can delay finding the real cause.
Proven ways to sleep better
- CBT for insomnia (CBT-I). A structured, short-term therapy that is a recommended first-line treatment for chronic insomnia in adults.
- A steady schedule. Go to bed and wake up at about the same time every day.
- A dark, quiet, cool room. Blackout curtains, a sleep mask or white noise can help.
- Limit caffeine later in the day and limit alcohol. Alcohol can make you drowsy but tends to break up sleep later in the night.
- Daytime activity and morning light.
If you are on a GLP-1 or another prescribed medicine and notice sleep changes, mention it at your next visit. Our post on sleep, stress and weight loss covers how sleep ties into health goals, and the PepSteady app can help you log sleep alongside medicines.
The bottom line
DSIP has a catchy name and a long research history, but the human evidence for better sleep is weak and inconsistent. It is not FDA-approved, and an FDA advisory panel declined to back it for compounding in 2026. For lasting sleep improvement, work with a clinician on proven options like CBT-I.
Sources
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study (PubMed)
- Delta-sleep-inducing peptide (DSIP): a review (PubMed)
- Diurnal rhythm of plasma delta-sleep-inducing peptide in humans (PubMed)
- FDA Panel Backs 6 Peptides for Compounding (AJMC)
Frequently asked questions
Does DSIP work for insomnia?
The evidence is mixed. Some small studies in the 1980s and early 1990s reported modest effects, while a double-blind study in people with chronic insomnia found little benefit. No large modern trials have shown that it works.
Is DSIP FDA-approved?
No. DSIP (also called emideltide) is not FDA-approved. In July 2026 an FDA advisory committee voted 7-6 against recommending it for the compounding list.
What actually helps chronic insomnia?
Cognitive behavioral therapy for insomnia (CBT-I) is a recommended first-line treatment for chronic insomnia in adults. A clinician can also check for sleep apnea, restless legs, mood problems or medicines that disturb sleep.